Zai Lab Ltd (ZLAB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Zai Lab Ltd, along with its peers in the biotechnology and biopharmaceutical sector, has been subject to significant fluctuations in stock prices. This volatility heightens the company’s susceptibility to securities class action lawsuits. Such litigation typically trails a downturn in a firm’s market value and, regardless of merit, can impose heavy financial burdens on the company. Moreover, a drawn-out legal battle could distract Zai Lab Ltd’s management and drain resources, potentially damaging the company’s operations and future prospects.
Overall, Wall Street has a Strong Buy consensus rating on ZLAB stock based on 6 Buys.
To learn more about Zai Lab Ltd’s risk factors, click here.
